Información: Esta es una versión obsoleta del modelo de datos. En la sección izquierda, bajo "Versiones", se encuentra el historial de versiones. Puede acceder a la versión actual a través del siguiente link: here.
Información:
Error:
ID
34574
Descripción
Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02454179
Link
https://clinicaltrials.gov/show/NCT02454179
Palabras clave
Versiones (2)
- 19/1/19 19/1/19 -
- 28/5/21 28/5/21 -
Titular de derechos de autor
see on clinicaltrials.gov
Subido en
19 de enero de 2019
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Squamous Cell Carcinoma of the Head and Neck NCT02454179
Eligibility Squamous Cell Carcinoma of the Head and Neck NCT02454179
- StudyEvent: Eligibility
Similar models
Eligibility Squamous Cell Carcinoma of the Head and Neck NCT02454179
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
ID.1
Item
men and women ≥ 18 years of age
boolean
ID.2
Item
histologically or cytologically confirmed recurrent, metastatic or unresectable hnscc of the oral cavity, oropharynx, hypopharynx, and larynx that that has either progressed during or after platinum-based chemotherapy administered for metastatic disease or has recurred during or within 6 months after the completion of platinum-based neoadjuvant or adjuvant therapy
boolean
ID.3
Item
presence of radiographically measurable disease as defined by recist 1.1
boolean
ID.4
Item
ecog performance status of 0 or 1
boolean
ID.5
Item
prior malignancy (other than hnscc), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥ 2 years or which will not limit survival to < 2 years
boolean
ID.6
Item
known central nervous system metastases and/or carcinomatous meningitis
boolean
ID.7
Item
a life-threatening illness, medical condition (including psychiatric conditions) or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety
boolean
ID.8
Item
significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of starting study drug
boolean